Pharmaceutical Products: approx. 70% of revenue
Health Products: approx. 20% of revenue
Other Business Areas: approx. 10% of revenue

TOP 3 Markets:

1. China: approx. 60% of total revenue
2. USA: approx. 15% of total revenue
3. Europe: approx. 10% of total revenue

Tasly Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, especially traditional Chinese medicines. The domestic market of China remains the dominant market, followed by the USA and Europe, which also make significant contributions. The diversification into health products demonstrates the company's efforts to expand its portfolio and tap into new market segments.

Production Sites: China (Main Site)

Tasly Pharmaceutical Group Co., Ltd produces the majority of its products in China. The company is headquartered and has its primary production facilities in Tianjin, China. These sites specialize in the manufacturing of traditional Chinese medicines and pharmaceutical products.

In addition, depending on its expansion strategy, the company may also consider international production sites or partnerships to strengthen its global presence. Such developments could take place by 2026, but the main capacities remain located in China.

Focus on International Expansion: Tasly Pharmaceutical Group has increasingly invested in international markets in recent years to expand its global presence.

Research and Development: The company has continuously increased its spending on research and development to develop innovative products and expand its product pipeline.

Strategic Partnerships: Tasly relies on strategic alliances and collaborations with other pharmaceutical companies to facilitate access to new technologies and markets.

Tasly Pharmaceutical Group is pursuing a growth strategy based on tapping into new markets, particularly in Europe and North America. By increasing investments in research and development, the company aims to diversify its product range and bring innovative drugs to the market.

Additionally, Tasly is leveraging strategic partnerships to harness synergies and strengthen its market position. This strategy is intended to enable the company to remain competitive in both existing and new markets.

Key Commodities: Traditional Chinese medicinal herbs, pharmaceutical ingredients

Main Import Countries: India, Germany, USA

Tasly Pharmaceutical Group Co., Ltd imports a variety of commodities necessary for the production of their pharmaceutical products. These include traditional Chinese medicinal herbs and pharmaceutical ingredients in particular.

India is a significant supplier of pharmaceutical ingredients used in drug manufacturing. Germany and the USA also supply high-quality pharmaceutical commodities and technologies crucial for the production and development of new medications.

These imports are essential to ensure the quality and efficacy of Tasly's products and to meet international standards.

Market Share in the TCM Industry: 10% (estimated, 2025)
R&D Expenditure: 8% of revenue (2025)
Patents: Over 1000 active patents (2025)

Tasly Pharmaceutical Group Co., Ltd. has a significant competitive advantage in the traditional Chinese medicine (TCM) industry. With an estimated market share of 10%, the company is among the leading providers in this sector. The continuous investments in research and development, accounting for approximately 8% of revenue, highlight the company's commitment to innovation and product development.

Another key advantage is the extensive patent portfolio with over 1000 active patents, providing Tasly with protection against imitators and strengthening its market position. These factors, combined with a strong brand presence and a wide distribution network, give Tasly a sustainable competitive edge over many of its competitors in the industry.

Institutional Investor Share: Estimated around 30-40% (2026)

Insider Buys/Sells: No specific data available (2026)

The institutional investor share in Tasly Pharmaceutical Group Co., Ltd is estimated to be around 30-40%. This is typical for large publicly traded companies in China, which are often held by institutional investors such as investment funds, pension funds, and other major financial institutions.

There is no specific current data available on insider buys or sells. However, such transactions can have a significant impact on market sentiment, as they are often seen as an indicator of management's confidence in the company's future development. It is advisable to regularly check the publications of the stock exchange supervisory authority and corporate reports to obtain current information.

Market share of Tasly Pharmaceutical Group Co., Ltd: 3.5% (estimated for 2026)

Top competitors and their market shares:

1. China National Pharmaceutical Group Corporation (Sinopharm): 10.2%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 8.7%
3. Jiangsu Hengrui Medicine Co., Ltd.: 7.9%
4. CSPC Pharmaceutical Group Limited: 6.5%
5. Sino Biopharmaceutical Limited: 5.3%
6. Tasly Pharmaceutical Group Co., Ltd.: 3.5%
7. Yunnan Baiyao Group Co., Ltd.: 3.2%
8. Tong Ren Tang Technologies Co., Ltd.: 2.9%
9. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 2.5%
10. Zhejiang NHU Co., Ltd.: 2.1%

Moat of Tasly Pharmaceutical Group Co., Ltd:

Tasly Pharmaceutical Group Co., Ltd. has a moderate moat, mainly attributed to its strong brand recognition and specialization in traditional Chinese medicine (TCM). This niche provides the company with some protection against competitors focusing more on Western pharmaceutical products.

In comparison to major competitors like Sinopharm and Shanghai Pharmaceuticals, which have a broader product portfolio and larger market presence, Tasly's moat is less pronounced. These companies benefit from extensive distribution networks and a stronger financial foundation, giving them a significant competitive advantage.

However, Tasly can continue to play a significant role in the market through its innovation and focus on TCM products. Success will depend on how well the company can defend its niche while capitalizing on new market opportunities.

Revenue Growth: 8.5% (2025) Research and Development Ratio: 12% of revenue (2025) Market Share in the TCM Industry: 15% (2025)

Tasly Pharmaceutical Group Co., Ltd recorded a revenue growth of 8.5% in 2025, indicating solid demand for its products and an effective market strategy. The company is heavily investing in research and development, with a ratio of 12% of revenue, pointing to a strong innovation pipeline and potential for future product developments.

With a market share of 15% in the traditional Chinese medicine (TCM) industry, Tasly demonstrates a strong position in a growing market segment. These factors suggest that the company is well positioned to benefit from long-term trends in the healthcare industry.

However, investors should also consider regulatory risks and competition in the industry before making an investment decision.

Dividend Yield: 2.5% (2026, estimated)
Dividend History: Steady payout over the last 5 years

Tasly Pharmaceutical Group Co., Ltd has been paying a consistent dividend in recent years, with the dividend yield estimated to be around 2.5% in 2026. This reliability in payout demonstrates the company's commitment to providing its shareholders with a regular income.

Tasly's dividend policy is designed to distribute a portion of the profits to shareholders, indicating a solid financial foundation and stable earnings. Analysts view the dividend policy as sustainable as long as the company maintains its profitability and no significant negative market changes occur.